{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:15:14Z","timestamp":1778667314321,"version":"3.51.4"},"reference-count":134,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006492","name":"NIAID DIR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jaci.2025.06.029","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T19:24:08Z","timestamp":1751916248000},"page":"579-589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evolution of mast cell research associated with the Laboratory of Allergic Diseases, 1985-2022: Summary of the 2023 NIAID Symposium"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-9406","authenticated-orcid":false,"given":"Hirsh D.","family":"Komarow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimichi","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoseph","family":"Mekori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Olivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knut","family":"Brockow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Cruse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy D.","family":"Klion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason R.","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Castells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melody C.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2025.06.029_bib1","doi-asserted-by":"crossref","first-page":"10743","DOI":"10.7150\/thno.46719","article-title":"Mast cells as a unique hematopoietic lineage and cell system: from Paul Ehrlich\u2019s visions to precision medicine concepts","volume":"10","author":"Valent","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jaci.2025.06.029_bib2","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2025.06.029_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev-pathmechdis-031521-042618","article-title":"New insights into the pathogenesis of mastocytosis: emerging concepts in diagnosis and therapy","volume":"18","author":"Valent","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jaci.2025.06.029_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"issue":"5619","key":"10.1016\/j.jaci.2025.06.029_bib5","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/268442a0","article-title":"Development of mast cells from grafted bone marrow cells in irradiated mice","volume":"268","author":"Kitamura","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2025.06.029_bib6","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.4049\/jimmunol.146.5.1410","article-title":"Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells","volume":"146","author":"Kirshenbaum","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib7","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.4049\/jimmunol.151.8.4221","article-title":"Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly\u2212, CD14\u2212, CD17\u2212, colony-forming cell","volume":"151","author":"Agis","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib8","doi-asserted-by":"crossref","first-page":"11408","DOI":"10.1073\/pnas.0504197102","article-title":"Identification of mast cell progenitors in adult mice","volume":"102","author":"Chen","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2025.06.029_bib9","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2002-01-0203","article-title":"Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene","volume":"100","author":"Yavuz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2025.06.029_bib10","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4049\/jimmunol.148.3.772","article-title":"Effect of IL-3 and stem cell factor on the apperance of human basophils and mast cells from CD34+ pluripotent progenitor cells","volume":"148","author":"Kirshenbaum","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000365729","article-title":"A ten-year retrospective analysis of the distribution, use and phenotypic characteristics of the LAD2 human mast cell line","volume":"164","author":"Kirshenbaum","year":"2014","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0145-2126(02)00343-0","article-title":"Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma\/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI","volume":"27","author":"Kirshenbaum","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2025.06.029_bib13","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood.V94.7.2333.419k30_2333_2342","article-title":"Demonstration that human mast cells arise from a progenitor cell population that is CD34+, c-kit+, and expresses aminopeptidase N (CD13)","volume":"94","author":"Kirshenbaum","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2025.06.029_bib14","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood.V84.8.2489.2489","article-title":"Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from a CD34+ Fc\u03b5RI\u2212 cell population","volume":"84","author":"Rottem","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2025.06.029_bib15","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.4049\/jimmunol.159.8.4006","article-title":"Fas (CD95, APO-1) antigen expression and function in murine mast cells","volume":"159","author":"Hartmann","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011083031272","article-title":"Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL","volume":"21","author":"Mekori","year":"2001","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2567.1998.00559.x","article-title":"Fas ligand (FasL, CD95L, APO-1L) expression in murine mast cells","volume":"94","author":"Wagelie-Steffen","year":"1998","journal-title":"Immunology"},{"key":"10.1016\/j.jaci.2025.06.029_bib18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMoa1500611","article-title":"Vibratory urticaria associated with a missense variant in ADGRE2","volume":"374","author":"Boyden","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.06.029_bib19","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.4049\/jimmunol.164.8.4332","article-title":"Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: up-regulation by IFN-gamma","volume":"164","author":"Okayama","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib20","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.4049\/jimmunol.166.7.4705","article-title":"A comparison of mediators released or generated by IFN-gamma-treated human mast cells following aggregation of Fc gamma RI or Fc epsilon RI","volume":"166","author":"Okayama","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clim.2007.07.008","article-title":"Hyperexpression of FcgammaRI and Toll-like receptor 4 in the intestinal mast cells of Crohn\u2019s disease patients","volume":"125","author":"Kobayashi","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/art.37741","article-title":"Activation of human synovial mast cells from rheumatoid arthritis or osteoarthritis patients in response to aggregated IgG through Fcgamma receptor I and Fcgamma receptor II","volume":"65","author":"Lee","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2025.06.029_bib23","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1038\/s41598-021-84963-7","article-title":"Higher PGD2 production by synovial mast cells from rheumatoid arthritis patients compared with osteoarthritis patients via miR-199a-3p\/prostaglandin synthetase 2 axis","volume":"11","author":"Mishima","year":"2021","journal-title":"Sci Rep"},{"issue":"3 pt 1","key":"10.1016\/j.jaci.2025.06.029_bib24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0091-6749(99)70316-7","article-title":"Mast cell\u2013T cell interactions","volume":"104","author":"Mekori","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib25","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.4049\/jimmunol.160.8.4026","article-title":"Induction and enhancement of Fc\u03b5RI-dependent mast cell degranulation following coculture with activated T cells: dependency on ICAM-1\u2013 and leukocyte function\u2013associated antigen (LFA)-1\u2013mediated heterotypic aggregation","volume":"160","author":"Inamura","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib26","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jaci.2008.07.024","article-title":"Stimulation of human mast cells by activated T cells leads to N-Ras activation through Ras guanine nucleotide releasing protein 1","volume":"122","author":"Shefler","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib27","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.4049\/jimmunol.167.7.4008","article-title":"Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha","volume":"167","author":"Baram","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib28","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2007.08.054","article-title":"Human mast cells release oncostatin M on contact with activated T cells: possible biologic relevance","volume":"121","author":"Salamon","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib29","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood.2023020515","article-title":"Tumor necrosis factor alpha promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis","volume":"143","author":"Greiner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2025.06.029_bib30","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.ajpath.2011.01.020","article-title":"Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V\u2013positive systemic mastocytosis","volume":"178","author":"Hoermann","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2025.06.029_bib31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaci.2013.04.035","article-title":"T cell\u2013derived microvesicles induce mast cell production of IL-24: relevance to inflammatory skin diseases","volume":"133","author":"Shefler","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib32","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.jaci.2017.06.045","article-title":"MicroRNA-4443 regulates mast cell activation by T cell\u2013derived microvesicles","volume":"141","author":"Shefler","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2023.03.005","article-title":"Extracellular vesicles as mediators of mast cell cross talk with immune cells: possible druggable targets","volume":"152","author":"Shefler","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107718","article-title":"Emerging mechanisms contributing to mast cell\u2013mediated pathophysiology with therapeutic implications","volume":"220","author":"Falduto","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"15","key":"10.1016\/j.jaci.2025.06.029_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155464","article-title":"FcepsilonRI signaling in the modulation of allergic response: role of mast cell\u2013derived exosomes","volume":"21","author":"Lecce","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"17","key":"10.1016\/j.jaci.2025.06.029_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179176","article-title":"Extracellular vesicles as emerging players in intercellular communication: relevance in mast cell\u2013mediated pathophysiology","volume":"22","author":"Shefler","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2025.06.029_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/jex2.139","article-title":"Activation of the receptor KIT induces the secretion of exosome-like small extracellular vesicles","volume":"3","author":"Pfeiffer","year":"2024","journal-title":"J Extracell Biol"},{"key":"10.1016\/j.jaci.2025.06.029_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12272","article-title":"Selective immunocapture reveals neoplastic human mast cells secrete distinct microvesicle- and exosome-like populations of KIT-containing extracellular vesicles","volume":"11","author":"Pfeiffer","year":"2022","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.jaci.2025.06.029_bib39","doi-asserted-by":"crossref","first-page":"E10692","DOI":"10.1073\/pnas.1809938115","article-title":"Mastocytosis-derived extracellular vesicles exhibit a mast cell signature, transfer KIT to stellate cells, and promote their activation","volume":"115","author":"Kim","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2025.06.029_bib40","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/s41467-021-22754-4","article-title":"Mastocytosis-derived extracellular vesicles deliver miR-23a and miR-30a into pre-osteoblasts and prevent osteoblastogenesis and bone formation","volume":"12","author":"Kim","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.06.029_bib41","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaci.2025.06.029_bib42","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.iac.2014.01.002","article-title":"Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms","volume":"34","author":"Cruse","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2025.06.029_bib43","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ymthe.2021.08.009","article-title":"Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasms","volume":"30","author":"Snider","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2025.06.029_bib44","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2025.06.029_bib45","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2025.06.029_bib46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10428190400010775","article-title":"Mastocytosis: pathology, genetics, and current options for therapy","volume":"46","author":"Valent","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaci.2025.06.029_bib47","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood.V96.4.1267","article-title":"Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology","volume":"96","author":"Akin","year":"2000","journal-title":"Blood"},{"issue":"3 suppl","key":"10.1016\/j.jaci.2025.06.029_bib48","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1111\/1523-1747.ep12468882","article-title":"Classification and diagnosis of mastocytosis: current status","volume":"96","author":"Metcalfe","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.06.029_bib49","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.jaci.2025.06.029_bib50","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1182\/blood.V98.4.1195","article-title":"The Kit-activating mutation D816V enhances stem cell factor\u2013dependent chemotaxis","volume":"98","author":"Taylor","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2025.06.029_bib51","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(01)00023-6","article-title":"Slowly progressive systemic mastocytosis with high mast-cell burden and no evidence of a non\u2013mast-cell hematologic disorder: an example of a smoldering case?","volume":"25","author":"Akin","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2025.06.029_bib52","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib53","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2222.1990.tb02775.x","article-title":"Mast cells in cutaneous mastocytosis: accumulation of the MCTC type","volume":"20","author":"Irani","year":"1990","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2025.06.029_bib54","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jaci.2015.05.034","article-title":"Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis","volume":"136","author":"Wiechers","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib55","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.3390\/ijms22052586","article-title":"Molecular background, clinical features and management of pediatric mastocytosis: status 2021","volume":"22","author":"Lange","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2025.06.029_bib56","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1016\/j.jaip.2024.08.044","article-title":"Harmonization of diagnostic criteria in mastocytosis for use in clinical practice: WHO vs ICC vs AIM\/ECNM","volume":"12","author":"Valent","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.06.029_bib57","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00105-023-05168-9","article-title":"[Mastocytosis in children]","volume":"74","author":"Wassmer","year":"2023","journal-title":"Dermatologie (Heidelb)"},{"key":"10.1016\/j.jaci.2025.06.029_bib58","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jid.2020.12.030","article-title":"Clinical impact of skin lesions in mastocytosis: a multicenter study of the European Competence Network on Mastocytosis","volume":"141","author":"Aberer","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.06.029_bib59","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.jaip.2023.02.021","article-title":"European Competence Network on Mastocytosis (ECNM): 20-year jubilee, updates, and future perspectives","volume":"11","author":"Valent","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.06.029_bib60","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus placebo in indolent systemic mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jaci.2025.06.029_bib61","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.06.029_bib62","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","article-title":"Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis","volume":"146","author":"Hartmann","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib63","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.iac.2016.08.017","article-title":"Mastocytosis and anaphylaxis","volume":"37","author":"Schuch","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2025.06.029_bib64","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.jaip.2023.05.012","article-title":"Disease spectrum of anaphylaxis disorders","volume":"11","author":"Gonzalez de Olano","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.06.029_bib65","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.jaip.2023.03.015","article-title":"Research advances in mast cell biology and their translation into novel therapies for anaphylaxis","volume":"11","author":"Dispenza","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.06.029_bib66","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.937990","article-title":"Prevalence and variability of allergen-specific immunoglobulin E in patients with elevated tryptase levels","volume":"28","author":"Cerniauskiene","year":"2022","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jaci.2025.06.029_bib67","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjh.17714","article-title":"Decoding the intricacies of the mast cell compartment","volume":"196","author":"Carter","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2025.06.029_bib68","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib69","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anai.2023.09.015","article-title":"Anaphylaxis: a 2023 practice parameter update","volume":"132","author":"Golden","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib70","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3390\/ijms22052684","article-title":"Mediator-related symptoms and anaphylaxis in children with mastocytosis","volume":"22","author":"Brockow","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2025.06.029_bib71","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1067\/mjd.2003.98","article-title":"Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology","volume":"48","author":"Brockow","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.06.029_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2025.1570123","article-title":"Fire ant-venom anaphylaxis prevalence in the general population and patients with systemic mastocytosis","volume":"6","author":"McMurray","year":"2025","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaci.2025.06.029_bib73","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","article-title":"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \u201cidiopathic\u201d anaphylaxis","volume":"110","author":"Akin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2025.06.029_bib74","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","article-title":"Epidemiology, prognosis, and risk factors in mastocytosis","volume":"34","author":"Brockow","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2025.06.029_bib75","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib76","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaci.2017.05.036","article-title":"A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis","volume":"141","author":"Carter","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib134","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/cea.13798","article-title":"A study of microbial translocation markers in mastocytosis","volume":"51","author":"Komarow","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2025.06.029_bib78","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1016\/j.jaip.2020.05.044","article-title":"Low frequency of IgE-mediated food hypersensitivity in mastocytosis","volume":"8","author":"Jarkvist","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.06.029_bib79","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaci.2018.10.063","article-title":"Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: a work group report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology","volume":"143","author":"Carter","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib80","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jaip.2024.03.040","article-title":"Drug-induced anaphylaxis uncommon in mastocytosis: findings from two large cohorts","volume":"12","author":"Beyens","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.06.029_bib81","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","article-title":"Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis","volume":"316","author":"Schwartz","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.06.029_bib82","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2025.06.029_bib83","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.anai.2021.06.019","article-title":"Inherited and acquired determinants of serum tryptase levels in humans","volume":"127","author":"Lyons","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib77","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1182\/bloodadvances.2022007936","article-title":"Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms","volume":"7","author":"Chovanec","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaci.2025.06.029_bib84","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11882-024-01136-y","article-title":"Alpha-tryptase as a risk-modifying factor for mast cell\u2013mediated reactions","volume":"24","author":"Shin","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2025.06.029_bib85","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased alpha-tryptase\u2013encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib86","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/all.15911","article-title":"Clinical impact of the TPSAB1 genotype in mast cell diseases: a REMA study in a cohort of 959 individuals","volume":"79","author":"Gonzalez-de-Olano","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.06.029_bib87","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1084\/jem.20190701","article-title":"Impact of naturally forming human alpha\/beta-tryptase heterotetramers in the pathogenesis of hereditary alpha-tryptasemia","volume":"216","author":"Le","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2025.06.029_bib88","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jaci.2023.07.014","article-title":"Severe food allergy reactions are associated with alpha-tryptase","volume":"152","author":"Lang","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib89","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/imr.12638","article-title":"Human eosinophils and mast cells: birds of a feather flock together","volume":"282","author":"Robida","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2025.06.029_bib90","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jaci.2024.07.025","article-title":"Interactions between eosinophils and IL-5Ralpha\u2013positive mast cells in nonadvanced systemic mastocytosis","volume":"154","author":"Lefevre","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib91","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0145-2126(03)00065-1","article-title":"Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia","volume":"27","author":"Pardanani","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2025.06.029_bib92","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2005.05863.x","article-title":"Multilineage involvement of the fusion gene in patients with FIP1L1\/PDGFRA-positive hypereosinophilic syndrome","volume":"132","author":"Robyn","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2025.06.029_bib93","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2007.05.024","article-title":"KIT D816V\u2013associated systemic mastocytosis with eosinophilia and FIP1L1\/PDGFRA-associated chronic eosinophilic leukemia are distinct entities","volume":"120","author":"Maric","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib94","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41375-019-0632-4","article-title":"Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry","volume":"34","author":"Kluin-Nelemans","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2025.06.029_bib95","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti\u2013Siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.06.029_bib96","article-title":"Targeting of the IL-5 pathway in severe asthma reduces mast cell progenitors","author":"Alvarado-Vazquez","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib97","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221435","article-title":"Emerging functions of tissue-resident eosinophils","volume":"220","author":"Gurtner","year":"2023","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2025.06.029_bib98","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000500088","article-title":"Physiological roles of mast cells: Collegium Internationale Allergologicum update, 2019","volume":"179","author":"Varricchi","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib99","doi-asserted-by":"crossref","first-page":"521","DOI":"10.18632\/oncotarget.28614","article-title":"Prevalence and impact of the KIT M541L variant in patients with mastocytosis","volume":"15","author":"Aldama","year":"2024","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaci.2025.06.029_bib100","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.06.029_bib101","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.06.029_bib102","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.jaip.2022.03.007","article-title":"Personalized management strategies in mast cell disorders: ECNM-AIM user\u2019s guide for daily clinical practice","volume":"10","author":"Valent","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.06.029_bib103","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jaci.2020.11.005","article-title":"A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis","volume":"147","author":"Carter","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib104","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1016\/j.jaip.2021.08.001","article-title":"Assessment of osteoporosis and fracture risk in mastocytosis within a North American cohort","volume":"9","author":"Makovoz","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.06.029_bib105","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","article-title":"The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions","volume":"2","author":"Jennings","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.06.029_bib106","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/bjh.15624","article-title":"Detection of KIT D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease","volume":"183","author":"Carter","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2025.06.029_bib107","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2025.06.029_bib108","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2025.06.029_bib109","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3324\/haematol.11836","article-title":"Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion","volume":"93","author":"Lahortiga","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2025.06.029_bib110","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"Midostaurin (PKC412) inhibits immunoglobulin E\u2013dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2025.06.029_bib111","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","article-title":"Midostaurin: a magic bullet that blocks mast cell expansion and activation","volume":"28","author":"Valent","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaci.2025.06.029_bib112","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.jaci.2022.04.020","article-title":"Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: are we there yet?","volume":"149","author":"Akin","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib113","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"issue":"414","key":"10.1016\/j.jaci.2025.06.029_bib114","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2025.06.029_bib115","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2025.06.029_bib116","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2025.06.029_bib117","series-title":"Paper presented at: European Hematology Association (EHA) Conference","article-title":"Avapritinib in patients with advanced systemic mastocytosis (AdvSM): efficacy and safety analysis from the phase 2 PATHFINDER study with 3- year follow-up","author":"Reiter","year":"2024"},{"key":"10.1016\/j.jaci.2025.06.029_bib118","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2010.031690","article-title":"Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis","volume":"96","author":"Wilson","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2025.06.029_bib119","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bmt.1705245","article-title":"A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis","volume":"37","author":"Nakamura","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2025.06.029_bib120","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","article-title":"Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2025.06.029_bib121","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib122","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib123","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.jaip.2022.05.007","article-title":"Global classification of mast cell activation disorders: an ICD-10-CM\u2013adjusted proposal of the ECNM-AIM Consortium","volume":"10","author":"Valent","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.06.029_bib124","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaci.2024.05.025","article-title":"Mast cell activation syndrome: current understanding and research needs","volume":"154","author":"Castells","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib125","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/PAS.0000000000001676","article-title":"Distinct small intestine mast cell histologic changes in patients with hereditary alpha-tryptasemia and mast cell activation syndrome","volume":"45","author":"Hamilton","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jaci.2025.06.029_bib126","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.anai.2021.10.006","article-title":"Mast cell disorders are associated with decreased cerebral blood flow and small fiber neuropathy","volume":"128","author":"Novak","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib127","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jaci.2022.04.025","article-title":"Differential mast cell mediators in systemic mastocytosis and hereditary alpha-tryptasemia","volume":"150","author":"Giannetti","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.029_bib128","doi-asserted-by":"crossref","first-page":"40261","DOI":"10.1074\/jbc.M506063200","article-title":"Btk plays a crucial role in the amplification of Fc epsilonRI-mediated mast cell activation by kit","volume":"280","author":"Iwaki","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2025.06.029_bib129","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/all.15657","article-title":"Legends of allergy and immunology: Dean D. Metcalfe","volume":"78","author":"Akin","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.06.029_bib130","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1172\/JCI85538","article-title":"Different activation signals induce distinct mast cell degranulation strategies","volume":"126","author":"Gaudenzio","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2025.06.029_bib131","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/s41596-019-0288-6","article-title":"Rapid identification of human mast cell degranulation regulators using functional genomics coupled to high-resolution confocal microscopy","volume":"15","author":"Folkerts","year":"2020","journal-title":"Nat Protoc"},{"issue":"12","key":"10.1016\/j.jaci.2025.06.029_bib132","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146572","article-title":"The role of Sp140 revealed in IgE and mast cell responses in Collaborative Cross mice","volume":"6","author":"Matsushita","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2025.06.029_bib133","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s40629-020-00118-6","article-title":"Mast cells and IgE in defense against lethality of venoms: possible \u201cbenefit\u201d of allergy","volume":"29","author":"Galli","year":"2020","journal-title":"Allergo J Int"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925007390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925007390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:36:28Z","timestamp":1778664988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674925007390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":134,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0091674925007390"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2025.06.029","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of mast cell research associated with the Laboratory of Allergic Diseases, 1985-2022: Summary of the 2023 NIAID Symposium","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2025.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}